Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma
{{output}}
Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent lymphoma. This comp... ...
